CCR4 and neoplasm: A defucosylated anti-CC chemokine receptor 4 (CCR4), mogamulizumab, not only induces ADCC against CCR4+ malignant T cells but also reduces CCR4+ regulatory T cells (Tregs) which in turn restores NK cell anti-tumor function in patients with cutaneous T cell lymphoma (CTCL) [18].